The positive trial results for Novo Nordisk's high-dose oral drug semaglutide indicate that the drug may be effective in treating obesity, which could lead to increased demand for the drug and boost the company's position in the weight-loss treatment market. The company plans to seek regulatory approval later this year, which could further impact the stock price.